Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GlaxoSmithKline

Clinical trials of the vaccine will start this year, Sanofi CEO Paul Hudson said.

Sanofi partners with GSK for developing coronavirus vaccine

GlaxoSmithKline GSK, +0.15% and Sanofi SNY, -2.37% announced plans to jointly develop a COVID-19 vaccine candidate.

GSK, Sanofi to team up on COVID-19 vaccine

Sanofi: Ready To Ride The Volatile Market

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Sanofi (SNY) a Great Value Stock Right Now?

AstraZeneca

BioNTech SE

Moderna

Pfizer

Telesis Bio Inc

Biotech and big pharma are putting vaccines using messenger RNA to the coronavirus test.

Is mRNA the Key to a Coronavirus Vaccine?

France-based global drugmaker Sanofi SA (NYSE: SNY) is working on developing a coronavirus vaccine under the assumption the pandemic will resume "in some form" into 2021, CEO Paul Hudson said Wednesday in a Fox Business interview.

Sanofi CEO Talks Coronavirus Vaccine Development, Potential Treatment

Amgen

Bristol-Myers

Gilead Sciences

Merck

Track the latest trends and leading stocks in the biotech and pharmaceutical industries.

Biotech Stocks To Watch And Pharma Industry News

The drug touted by Trump for coronavirus has not been scientifically proven as an effective treatment.

Trump Has ‘Small,’ ‘Distant Link’ To Sanofi, French Drugmaker Of Hydroxychloroquine

Trump Reportedly Holds ‘Financial Interest’ In Sanofi, French Drugmaker Of Hydroxychloroquine

Regeneron Pharmaceuticals

Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.

Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis

Small studies using the decades-old malaria medication have suggested that it could speed up the recovery of those with the novel coronavirus.

CEO Says Sanofi Can Mass-Produce Hydroxychloroquine for COVID-19 Patients

Johnson & Johnson

Novavax

The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.

Coronavirus Drug & Vaccine: 4 Companies Leading From the Front

The FDA requests drugmakers to withdraw all ranitidine medications, which includes Sanofi's (SNY) popular heartburn drug Zantac, due to possible increase in risk of cancer.

Sanofi to Withdraw Zantac After FDA Warns of Carcinogens

Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.

Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus

US health regulators are telling drugmakers to immediately pull their popular heartburn drugs off the market after determining that a contamination issue with the medications poses a greater risk than previously thought.

Zantac heartburn drug recalled on contamination risk

All Zantac products and generic versions of the heartburn medication should be taken off pharmacy shelves immediately, the Food and Drug Administration announced Wednesday.

FDA orders all Zantac heartburn products off store shelves

The pharma company is making progress on its portfolio of coronavirus therapies and the execution of its new growth strategy.

Here's Why Sanofi Is An Underappreciated Coronavirus Stock

The agency says there is a risk that some of the heartburn pills may contain unacceptable levels of NDMA, a possible carcinogen.

FDA Asks for Recalls of Sanofi's Zantac and All Generic Versions

Shares of Sanofi [: sny] fell 1.78% in trading on Wednesday after the Food and Drug Administration (FDA) issued a voluntary recall of Sanofi's Zantac, a prescription and over-the-counter heartburn drug, following reports of a contaminant in those products. "We didn't observe unacceptable levels of [the contaminent] NDMA in many of the samples that we tested," Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in a statement.

FDA issues voluntary recall of heartburn drug Zantac

Inovio Pharmaceuticals

Vaxart

Just like the flu vaccine, pharmacists should be empowered to administer the COVID-19 vaccine to patients in every state.

Expand Pharmacists’ Authority To Promote COVID-19 Vaccine Access

Sanofi (SNY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Sanofi (SNY) Catches Eye: Stock Jumps 5.3%

Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.

Sanofi Begins Kevzara Study for Severe Coronavirus Infection

Sanofi (NYSE: SNY) shares are trading higher on Monday. The company reported the first patient outside of the U.S.

Why Sanofi's Stock Is Trading Higher Today

Abbott Labs

Novartis

Teva Pharmaceutical

Measures currently being taken against COVID-19 are the only means of containing and suppressing the virus.

Big Pharma Advances on COVID-19

Regeneron Pharmaceuticals Inc. REGN, -0.61% and Sanofi SA SNY, -1.19% said Monday that the first patient in a global clinical trial testing Kevzara as a therapy for patients hospitalized with severe cases of COVID-19 has been treated.

News for Sanofi Stock (SNY)